Aficamten in Obstructive Hypertrophic Cardiomyopathy: Durable 48-Week Benefits and Insights on Combination Therapy

Highlight

• Aficamten provided rapid, significant, and sustained reductions in left ventricular outflow tract (LVOT) obstruction over 48 weeks in symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
• 82% of patients experienced improvement by at least one NYHA functional class; cardiac remodeling was supported by reductions in left ventricular wall thickness and cardiac biomarkers.
• Combination therapy of aficamten and disopyramide was safe but did not enhance efficacy beyond aficamten alone; disopyramide discontinuation during aficamten treatment appears feasible.

Study Background and Disease Burden